RLMD
Price
$3.16
Change
+$0.06 (+1.94%)
Updated
Oct 19 closing price
Capitalization
337.08M
16 days until earnings call
Intraday BUY SELL Signals
RNAC
Price
$6.08
Change
-$0.19 (-3.03%)
Updated
Oct 19 closing price
Capitalization
183.95M
16 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

RLMD vs RNAC

RLMD vs RNAC Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
RLMD vs. RNAC commentary
Oct 20, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RLMD is a Hold and RNAC is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for RLMD with price predictions
Oct 19, 2026

RLMD's Indicator enters downward trend

The Aroon Indicator for RLMD entered a downward trend on October 19, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 238 similar instances where the Aroon Indicator formed such a pattern. In 203 of the 238 cases the stock moved lower. This puts the odds of a downward move at 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RLMD as a result. In 72 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.

The Moving Average Convergence Divergence Histogram (MACD) for RLMD turned negative on September 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 31 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RLMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RLMD's RSI Oscillator exited the oversold zone, 29 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +10.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where RLMD advanced for three days, in 230 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

RLMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.632) is normal, around the industry mean (2.978). P/E Ratio (-3.473) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (0.120) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (134.267) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. RLMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RLMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for RNAC with price predictions
Oct 19, 2026

RNAC in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 14, 2026

RNAC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 38 of 44 cases where RNAC's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +5.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where RNAC advanced for three days, in 218 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Bearish Trend Analysis

The 10-day moving average for RNAC crossed bearishly below the 50-day moving average on September 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNAC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for RNAC entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.469) is normal, around the industry mean (2.978). P/E Ratio (-1.052) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (134.267) among similar stocks. P/S Ratio (144.928) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. RNAC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNAC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
RLMD vs RNAC: Fundamental Ratings
RLMD
RNAC
OUTLOOK RATING
1..100
5969
VALUATION
overvalued / fair valued / undervalued
1..100
31
Undervalued
28
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
5050
P/E GROWTH RATING
1..100
1418
SEASONALITY SCORE
1..100
90n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RNAC's Valuation (28) in the Biotechnology industry is in the same range as RLMD (31) in the null industry. This means that RNAC’s stock grew similarly to RLMD’s over the last 12 months.

RNAC's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RLMD (100) in the null industry. This means that RNAC’s stock grew similarly to RLMD’s over the last 12 months.

RLMD's SMR Rating (98) in the null industry is in the same range as RNAC (100) in the Biotechnology industry. This means that RLMD’s stock grew similarly to RNAC’s over the last 12 months.

RLMD's Price Growth Rating (50) in the null industry is in the same range as RNAC (50) in the Biotechnology industry. This means that RLMD’s stock grew similarly to RNAC’s over the last 12 months.

RLMD's P/E Growth Rating (14) in the null industry is in the same range as RNAC (18) in the Biotechnology industry. This means that RLMD’s stock grew similarly to RNAC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RLMDRNAC
RSI
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
80%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
N/A
Momentum
ODDS (%)
Bearish Trend 4 days ago
83%
N/A
MACD
ODDS (%)
Bearish Trend 1 day ago
84%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 8 days ago
86%
Bullish Trend 11 days ago
83%
Declines
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
86%
Aroon
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Oct 20, 2026
Stock price -- (RLMD: $3.16 vs. RNAC: $6.08)
Brand notoriety: RLMD and RNAC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RLMD: 63% vs. RNAC: 118%
Market capitalization -- RLMD: $337.08M vs. RNAC: $183.95M
RLMD [@Biotechnology] is valued at $337.08M. RNAC’s [@Biotechnology] market capitalization is $183.95M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $127.22B. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RLMD’s FA Score shows that 2 FA rating(s) are green while RNAC’s FA Score has 2 green FA rating(s).

  • RLMD’s FA Score: 2 green, 3 red.
  • RNAC’s FA Score: 2 green, 3 red.
According to our system of comparison, both RLMD and RNAC are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RLMD’s TA Score shows that 4 TA indicator(s) are bullish while RNAC’s TA Score has 3 bullish TA indicator(s).

  • RLMD’s TA Score: 4 bullish, 4 bearish.
  • RNAC’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, both RLMD and RNAC are a good buy in the short-term.

Price Growth

RLMD (@Biotechnology) experienced а -9.97% price change this week, while RNAC (@Biotechnology) price change was -13.02% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.86%. For the same industry, the average monthly price growth was -18.66%, and the average quarterly price growth was -19.56%.

Reported Earning Dates

RLMD is expected to report earnings on Nov 05, 2026.

RNAC is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-7.86% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
RLMD
Daily Signal:
Gain/Loss:
RNAC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FHYS22.51-0.01
-0.04%
Federated Hermes Short Duration High Yield ETF (FHYS)
GSID74.14-0.41
-0.55%
Marketbeta INTL Equity ETF (GSID)
IJUL35.86-0.22
-0.60%
Innovator International Developed Power Buffer ETF - July (IJUL)
XLF55.06-0.46
-0.83%
State Street Financial Select Sector SPDR ETF (XLF)
NVDD30.28-0.45
-1.46%
Direxion Daily NVDA Bear 1X ETF (NVDD)